Astrazeneca (AZN) EBITDA Margin (2009 - 2026)
Astrazeneca (AZN) posted quarterly EBITDA Margin of 20.57% for Q2 2026, down 370.0% year-over-year from 7.62% in Q2 2025, and down 99.63% quarter-over-quarter from 5514.29% in Q1 2026.
Astrazeneca (AZN) EBITDA Margin (2009 - 2026) Analysis & Trends
Astrazeneca's EBITDA Margin history runs 18 years deep, the most recent figure standing at 20.57% for Q2 2026.
- In Q2 2026, EBITDA Margin fell 370.0% year-over-year to 20.57%; the TTM figure through Jun 2026 stood at 90.26% (up 1675.0% YoY), while the FY2025 annual figure was 23.4%, up 490.0% from the prior year.
- EBITDA Margin for Q2 2026 stood at 20.57%, down from 5514.29% in the prior quarter.
- The five-year high for EBITDA Margin was 68650.0% in Q2 2024, with the low at 20.57% in Q2 2026.
- The 5-year median for EBITDA Margin is 2882.38% (2023), against an average of 11540.91%.
- The sharpest annual moves came in 2024 and 2025: EBITDA Margin jumped 6737746 bps in 2024, then sank 6862573 bps in 2025.
- Astrazeneca's EBITDA Margin stood at 1685.44% in 2022, then jumped by 30 bps to 2195.27% in 2023, then plunged by 89 bps to 249.82% in 2024, then surged by 19768 bps to 49633.33% in 2025, then tumbled by 100 bps to 20.57% in 2026.
- Business Quant data shows AZN's EBITDA Margin at 20.57% in Q2 2026, 5514.29% in Q1 2026, and 49633.33% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 32.97% |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 20.57% |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 34.95% |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -133.21% |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 28.37% |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 5.72% |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 124.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.57% |
| Mar 31, 2026 | 5,514.29% |
| Dec 31, 2025 | 49,633.33% |
| Sep 30, 2025 | 32,572.73% |
| Jun 30, 2025 | 24.27% |
| Mar 31, 2025 | 4,964.86% |
| Dec 31, 2024 | 249.82% |
| Sep 30, 2024 | 3,569.49% |
| Jun 30, 2024 | 68,650.00% |
| Mar 31, 2024 | 6,922.22% |
| Dec 31, 2023 | 2,195.27% |
| Sep 30, 2023 | 2,014.43% |
| Jun 30, 2023 | 1,272.54% |
| Mar 31, 2023 | 9,440.74% |
| Dec 31, 2022 | 1,685.44% |
| Sep 30, 2022 | 699.44% |
| Jun 30, 2022 | 17,966.67% |
| Mar 31, 2022 | 340.31% |
| Dec 31, 2021 | -56.92% |
| Sep 30, 2021 | -1,339.20% |